GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
GSK Trading Down 4.0 %
NYSE:GSK traded down $1.43 during trading hours on Monday, hitting $34.60. 312,133 shares of the company were exchanged, compared to its average volume of 5,540,508. The stock has a market capitalization of $70.37 billion, a price-to-earnings ratio of 11.93, a price-to-earnings-growth ratio of 1.29 and a beta of 0.46. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 0.83. GSK has a one year low of $34.50 and a one year high of $46.97. The company has a fifty day simple moving average of $41.97 and a 200 day simple moving average of $43.21.
GSK Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 6th. Stockholders of record on Friday, August 19th will be given a $0.383 dividend. The ex-dividend date of this dividend is Thursday, August 18th. This is a positive change from GSK's previous quarterly dividend of $0.35. This represents a $1.53 annualized dividend and a dividend yield of 4.43%. GSK's dividend payout ratio (DPR) is 55.30%.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on the company. TheStreet raised GSK from a "c+" rating to an "a-" rating in a report on Friday, July 22nd. Citigroup reissued a "neutral" rating on shares of GSK in a report on Thursday, July 21st. Barclays raised their price objective on GSK from GBX 1,775 ($21.45) to GBX 1,800 ($21.75) in a report on Friday, April 29th. AlphaValue downgraded GSK to a "reduce" rating in a report on Tuesday, July 19th. Finally, JPMorgan Chase & Co. raised their price objective on GSK from GBX 1,740 ($21.02) to GBX 1,900 ($22.96) in a report on Thursday, April 28th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $1,787.50.